This submission's references do not show that the subject
qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published,
reliable,
secondary sources that are independent of the subject (see the
guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see
technical help and learn about
mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
If you would like to continue working on the submission, click on the "Edit" tab at the top of the window.
If you have not resolved the issues listed above, your draft will be declined again and potentially deleted.
If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors.
Please do not remove reviewer comments or this notice until the submission is accepted.
Where to get help
If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the
talk page of a
relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed.
To improve your odds of a faster review, tag your draft with relevant
WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.
Please note that if the issues are not fixed, the draft will be declined again.
Comment: I can't find anything in the draft that would conclusively make this notable under
WP:NACADEMIC. If that is what's being asserted, please clearly state which of the criteria 1–8 is met, and what evidence supports such an assertion. As for
WP:GNG notability, this is not established, as almost all the sources cited are works co-/authored by Coy himself.The citations are also wholly inadequate, with many passages unsupported, including the entire 'Awards' section. Private personal details such as
DOB and educational background are also not referenced. Please note that per
WP:BLP, in articles on living people all material statements, anything potentially contentious, and all private details must be clearly supported by immediate inline citations to reliable published sources.
DoubleGrazing (
talk) 08:26, 8 April 2023 (UTC)
Johannes F. Coy (*December 15, 1963 in
Otzberg) is a German
biologist and cancer researcher. He discovered the genes
TKTL1[1] and DNaseX[2] (Apo10)[3]. According to the latest findings in evolutionary research, TKTL1 is a key gene that triggered increased neuron formation in the neocortex and structural improvements in the brain compared to Neanderthals, thus enabling the cognitive achievements of modern humans (homo sapiens).[4]
Life and Scientific Work
Johannes Coy began his biology studies at the
Eberhard Karls University in
Tübingen in 1985, graduating in 1990 with a focus on molecular and human genetics and biochemistry. In the same year, he transferred to the German Cancer Center (DKFZ) in
Heidelberg, where, after completing his diploma thesis (mapping of a tumor suppressor gene in neuroblastoma), he became a member of the research project Molecular Genome Analysis under the direction of Prof.
Harald zur Hausen, then head of the DKFZ and later
Nobel Prize winner for Medicine.
During this time, he focused on the identification of genes and discovered the two genes TKTL1 and DNaseX (Apo10) in this context. He was awarded summa cum laude in 1996 for his dissertation based on the discovery of the two genes. From his analyses of TKTL1 and DNaseX (Apo10), Coy concluded that both genes hold the potential for new cancer markers for for diagnostic purposes.
In his further scientific work, Coy was from then on involved in the holistic study of tumor cell metabolism, in particular the application of the two genes for the early detection of cancer on the basis of diagnostic tests. He found that the simultaneous presence of TKTL1 and DNaseX (Apo10) in macrophages is indicative of a cancerous disease[3] and participated in the development of a blood test that detects TKTL1 and DNaseX (Apo10) in macrophages.[3]
He also discovered the TKTL1 metabolic pathway and the associated sugar metabolism that enables the prevention and repair of cellular damage.[5][6][7]
As a result of his research, Coy's diagnostic developments include:
Epitope detection in monocytes (EDIM) - Biomarker detection method in cells of the innate immune system in blood samples
Automated flow cytrometry method
Flow cytometry-based blood tests
Johannes Coy holds several patents in the field of cancer research and diagnostics, including DNaseX and TKTL1:
DNA encoding DNase and related vectors, host cells and antibodies (DNaseX)[8]
2007: Waltraut Fryda Prize: Awarded at the International Congress of Biological Cancer Medicine for clarifying the role of the TKTL1 gene in the fermentation metabolism of cancer cells.
2006: Diaita Science Prize: Awarded by the Gesellschaft für Ernährungsmedizin und Diätetik e.V. (now Fachgesellschaft für Ernährungstherapie und Prävention (FET) e.V.) at the Medica trade fair for outstanding scientific commitment in the field of cancer research, diagnostics and therapy.
Publications (selection)
2022
Blood-Test Based Targeted Visualization Enables Early Detection of Premalignant and Malignant Tumors in Asymptomatic Individuals[10]
2017
EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer.[11]
2016
A key role for transketolase-like 1 in tumor metabolic reprogramming[5]
2013
A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells.[12]
2009
Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells.[13]
2006
Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival. Warburg effect reinterpreted.[6]
2005
Mutations in the transketolase-like gene TKTL1. Clinical implications for neurodegenerative diseases, diabetes and cancer.[7]
2000
Functional characterization of DNase X, a novel endonuclease expressed in muscle cells.[14]
1996
Molecular cloning of tissue-specific transcripts of a transketolase-related gene. Implications for the evolution of new vertebrate genes.[1]
Isolation, differential splicing and protein expression of a DNase on the human X chromosome.[2]
^
abSantiago Diaz-Moralli, Esther Aguilar, Silvia Marin, Johannes F. Coy, Mieke Dewerchin, Maciek R. Antoniewicz, Oscar Meca-Cortés, Leen Notebaert, Bart Ghesquière, Guy Eelen, Timothy M. Thomson, Peter Carmeliet, Marta Cascante (2016-08-09), "A key role for transketolase-like 1 in tumor metabolic reprogramming", Oncotarget, vol. 7, no. 32, pp. 51875–51897,
doi:
10.18632/oncotarget.10429,
ISSN1949-2553,
PMC5239521,
PMID27391434{{
citation}}: CS1 maint: multiple names: authors list (
link)
^
abS Langbein, M Zerilli, A zur Hausen, W Staiger, K Rensch-Boschert, N Lukan, J Popa, M P Ternullo, A Steidler, C Weiss, R Grobholz, F Willeke, P Alken, G Stassi, P Schubert, J F Coy (Feb 2006), "Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted", British Journal of Cancer, vol. 94, no. 4, pp. 578–585,
doi:
10.1038/sj.bjc.6602962,
ISSN0007-0920,
PMC2361175,
PMID16465194{{
citation}}: CS1 maint: multiple names: authors list (
link)
^Johannes Coy (2017-04-20), "EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer", International Journal of Molecular Sciences, vol. 18, no. 4, p. 878,
doi:10.3390/ijms18040878,
ISSN1422-0067,
PMC5412459,
PMID28425973
^Martin Grimm, Steffen Schmitt, Peter Teriete, Thorsten Biegner, Arnulf Stenzl, Jörg Hennenlotter, Hans-Joachim Muhs, Adelheid Munz, Tatjana Nadtotschi, Klemens König, Jörg Sänger, Oliver Feyen, Heiko Hofmann, Siegmar Reinert, Johannes F Coy (Dec 2013), "A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells", BMC Cancer, vol. 13, no. 1, p. 569,
doi:10.1186/1471-2407-13-569,
ISSN1471-2407,
PMC4235042,
PMID24304513{{
citation}}: CS1 maint: multiple names: authors list (
link)